| __timestamp | Halozyme Therapeutics, Inc. | Takeda Pharmaceutical Company Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 22732000 | 520990000000 |
| Thursday, January 1, 2015 | 29245000 | 535405000000 |
| Friday, January 1, 2016 | 33206000 | 558755000000 |
| Sunday, January 1, 2017 | 31152000 | 495921000000 |
| Monday, January 1, 2018 | 10136000 | 659690000000 |
| Tuesday, January 1, 2019 | 45546000 | 1089764000000 |
| Wednesday, January 1, 2020 | 43367000 | 994308000000 |
| Friday, January 1, 2021 | 81413000 | 1106846000000 |
| Saturday, January 1, 2022 | 139304000 | 1244072000000 |
| Sunday, January 1, 2023 | 192361000 | 1431505000000 |
| Monday, January 1, 2024 | 159417000 | 1431505000000 |
Infusing magic into the data realm
In the ever-evolving pharmaceutical landscape, understanding cost dynamics is crucial. Takeda Pharmaceutical Company Limited and Halozyme Therapeutics, Inc. offer a fascinating study in contrasts. From 2014 to 2023, Takeda's cost of revenue surged by approximately 175%, peaking at 1.43 trillion in 2023. This reflects its expansive global operations and strategic acquisitions. Meanwhile, Halozyme's cost of revenue grew by an impressive 745% over the same period, reaching 192 million in 2023. This rapid increase underscores its aggressive R&D investments and niche market focus.
Takeda's consistent growth highlights its robust market presence, while Halozyme's exponential rise signals its potential as a disruptive force. The data for 2024 is incomplete, suggesting a need for ongoing analysis. These trends provide valuable insights for investors and industry analysts alike, emphasizing the importance of strategic cost management in the pharmaceutical sector.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Vertex Pharmaceuticals Incorporated vs Takeda Pharmaceutical Company Limited
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
Cost of Revenue Trends: Takeda Pharmaceutical Company Limited vs Agios Pharmaceuticals, Inc.
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and PTC Therapeutics, Inc.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.